Company: ATRA
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0000950170-25-059322
Chunk: 45

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 45
---
 and bonus target decisions for our named executive officers;

A market analysis of long-term incentive compensation of our executive officers compared to our peer group, which was reviewed with the Human Capital Committee and used to guide 2024 long-term equity compensation determinations; and

A market analysis of director compensation compared to our peer group, which was reviewed with the Human Capital Committee and used to guide decisions relating to the compensation payable to our non-employee directors.

The Human Capital Committee regularly evaluates the services of its consultant. The Human Capital Committee has assessed the independence of Pearl Meyer, consistent with Nasdaq listing standards and has concluded that the engagement of Pearl Meyer did not raise any conflict of interest.

Competitive Assessment

A key objective of our executive compensation program is to offer overall compensation packages to our executive officers that are competitive with the packages offered by companies with which we can compete for executive talent in the highly competitive cell therapy talent landscape. The Human Capital Committee consults with its independent compensation consultant to develop a peer group of companies to serve as the basis for comparing our executive compensation program to the market.

2024 Peer Group

With the assistance of its independent compensation consultant, the Human Capital Committee annually reviews the composition of the peer group to account for changes in both our business and the businesses of the companies in the peer group. While referencing the peer group compensation levels is helpful in determining market-competitive compensation for our named executive officers, the Human Capital Committee does not directly tie any pay elements to particular benchmarks within the peer group. Rather, peer data is one consideration, along with employee knowledge, skills and experience, individual performance, and scope of responsibilities, among other factors.

The peer group used to determine 2024 compensation consisted of companies with a market capitalization range (at time of determination) of approximately $60.0 million to $1.5 billion. At the time of adoption, our market capitalization approximated the 25thpercentile of the selected peers and our revenue was at the 55thpercentile. In developing the peer group, the Human Capital Committee considered several key qualitative and quantitative elements as set out below.

Sector and Stage —highly competitive and dynamic biotechnology industry, with an emphasis on pre-commercial biopharmaceutical companies within the cell and gene therapy area

Stage of Business —focus on later stage (Phase 3) pre-commercial companies, with an emphasis on oncology and cell and gene therapy

Market Capitalization —between approximately $60.0 million and $1.5 billion

Headcount — generally between 100